While attending The University of British Columbia (UBC), Tamer Mohamed, along with fellow graduate student Simon Beyer, began working at the Walus Laboratory on the development of a novel microfluidics-based bioprinting platform that could be used to fabricate human tissue constructs. One of the main reasons for their innovation was to potentially replace animal models in drug testing, which are costly, time-consuming and can have poor predictive accuracy. A few years went by and the two went on to win a MEMSCAP Design Award for their pioneering creation (the Lab-on-a-Printer Bioprinter) which would later become the basis for their startup, Aspect Biosystems. The UBC spinoff company was founded by Mohamed, Beyer, Konrad Walus (associate professor at UBC and head of the Walus Lab), and Sam Wadsworth, to turn their idea into a commercial product. The company quickly began providing pharmaceutical companies with high-efficacy tissue models that better mimicin vivoconditions, looking to improve the predictive accuracy of the front end drug discovery process. 3DPrint.com spoke to Mohamed to learn about his successful transition from graduate student to CEO of Aspect Biosystems.
Cofounders of Aspect Biosystems Tamer Mohamed and Simon Beyer at the Walus Lab when they were grad students
What was the inspiration behind Aspect Biosystems?
Aspect Biosystems was established with the vision of leveraging advancements in biology, microfluidics, and 3D printing to create technology-enabled therapeutics that will ultimately have a meaningful impact on patients. We are marrying our deep knowledge of human biology with cutting-edge 3D printing technology to create. Our story started almost a decade ago so weve spent years developing our foundational microfluidic bioprinting technology and are now applying our platform technology to create functional tissues, both internally through our proprietary programs, and with our partners around the world.
Can you tell me about the companys growth model?
Platform technologies often have the advantage of flexibility, as they could allow you to pursue multiple applications. This also presents a challenge though, in that it is easy to become unfocused. At Aspect, weve built a strategy that allows us to both focus and diversify. Internally, we are advancing proprietary tissue programs in regenerative medicine. But we also recognize that to achieve our vision of enabling human tissues on demand, we cant work alone. By providing access to our technology to partners around the world, we are able to create a network effect and tap into specific domain expertise. This allows our technology to be applied to a wide range of research purposes externally, without detracting resources or focus from our specific tissue programs internally. We collaborate with academia and industry on specific applications that allow us to fuel our growth and help generate revenue and a robust innovation pipeline.
How much has Aspect grown?
Aspect is the first and only company to leverage microfluidics to create functional tissue, and we are proud to pioneer this approach. Academically, we were one of the first groups in the world to print cells while at the UBC, so we see ourselves as pioneers in both bioprinting and platforms for creating tissue therapeutics. Five years ago, we had four full-time employees. Today we have a team of over 40 people focused on our mission and over 20 collaborations globally. We have attracted smart venture capital, partnered with some of the biggest names in our industry, and made major breakthroughs in applying our technology to create functional tissues. It is a great sign that, year-after-year, we continue to raise the bar. It is an even better sign that I believe the best is yet to come.
The Aspect Biosystem team celebrating Canada Day
What will the applications of this technology be in pharmaceutical research and drug trials?
I believe the opportunity with the highest value and best poised to make a significant impact on the pharmaceutical space is disease modeling. Using 3D bioprinting technology allows us to model diseases in a human-relevant system that would otherwise be difficult to study in animals or less sophisticated in vitro models. For example, working with GSK and Merck, we are leveraging our microfluidic 3D bioprinting platform to create physiologically-relevant 3D tissues containing patient-derived cells to assess the efficacy of anti-cancer drugs and to predict a patients response to treatment. This partnered program could unlock the discovery of novel therapeutic targets and the development of immuno-oncology therapeutics.
Would you tell us more about Aspects current and future work?
Our current internal programs are focused on orthopedic and metabolic diseases. On the orthopedic side, we are leveraging our deep knowledge of musculoskeletal biology and biomaterials to create knee meniscal replacements. On the metabolic side, we are focused on liver tissue and creating a therapeutic tissue for Type 1 diabetes. Externally, our partners around the world are using our 3D bioprinting technology to advance research in the brain, lungs, heart, pancreas, and kidneys, just to name a few. By being both focused internally and diversified externally, we are building a robust pipeline for the future. Our end goal is to enable the creation of human tissues on demand, and we know that we cant do it alone. Our network of academic researchers and industry partners are key to making our vision a reality.
How fast is the technology moving towards a future with lab-made functional organs?
We are focused on identifying specific diseases or biological malfunction inside the body and rationally designing advanced tissue therapeutics that address these areas of unmet medical need. So, while we may not actually be making something that looks exactly like an organ, we are recreating the biological function that has been lost or damaged to address the problem. For example, someone with Type 1 diabetes has a pancreas that is unable to perform the vital function of creating insulin. We dont necessarily need to engineer something for them that looks exactly like a pancreas instead, we are creating an implantable therapeutic tissue that replaces function that has been lost. In this case, that function is sensing glucose levels in the blood and biologically releasing insulin in response. This is an example of one of our internal programs a bioengineered pancreatic tissue therapeutic that restores a critical function that been lost due to an autoimmune disease.
Is Canada a great place to develop a bioprinting company?
Canada has a long and rich history in the field of regenerative medicine, going back to the discovery of stem cells in the 1960s. As a country, we have an opportunity to be a global leader in the field. At Aspect, we are proud to be part of these efforts. We are in ongoing discussions with different government groups as to how we can play a role in helping to lead the charge and the government has been embracing that. We have seen significant federal and provincial support for innovation and public/private partnerships, which definitely help stimulate growth in the field.
How disruptive is the technology you created?
By combining microfluidics with 3D printing, we are disrupting tissue engineering. We are able to programmatically process multiple cells and biologically-relevant materials in high-throughput to rationally design and produce functional tissues. We are constantly integrating new microfluidic processing units within our printhead technology and leveraging continuous advancements in the lab-on-a-chip space. With our microfluidic technology, we are generating a large amount of data. By using this data and machine learning, we are improving the quality and automation of the biomanufacturing process.
Ultimately, bioprinting is only as good as our understanding of biology and our understanding of biology is growing wider and deeper. We are combining state-of-the-art stem cell science with our microfluidic 3D printing technology to create tissue therapeutics. For example, we are combining insulin-secreting cells derived from human embryonic stem cells (hESCs) with our printing technology to create therapeutic tissues for patients with Type 1 diabetes.
- Human blastocyst-like structures generated entirely from pluripotent stem cells. Shifting the paradigm of developmental biology? - ESHRE - April 4th, 2021
- Human Embryonic Stem Cells (HESC) Market 2021 Is Rapidly Increasing Worldwide in Near Future | Top Companies Analysis- ESI BIO, Thermo Fisher,... - April 4th, 2021
- New Michigan law requires those receiving Johnson & Johnson vaccine be told it was developed using stem cells | TheHill - The Hill - April 4th, 2021
- Xenobots 2.0 are Here and Still Developed With Frog Stem Cells - Unite.AI - April 4th, 2021
- Global Human Embryonic Stem Cells Industry Market 2021 In-depth Industry Analysis, Growth By 2027:Lonza Group Ltd., Life Technologies Corporation,... - April 4th, 2021
- AgeX Therapeutics Reports Fourth Quarter and Annual 2020 Financial Results and Provides Business Update - Business Wire - April 4th, 2021
- Research Associate in Stem Cells and Regenerative Medicine job with KINGS COLLEGE LONDON | 246711 - Times Higher Education (THE) - February 17th, 2021
- Stem Cells Market Size 2021 by Share Growing Rapidly with Recent Trends, Size, Development, Revenue, Demand and Forecast to 2024 NeighborWebSJ -... - February 17th, 2021
- Cell transplant therapy could be a treatment for leading cause of blindness - The Denver Channel - February 17th, 2021
- Cellular Reprogramming Tools Market likely to touch new heights by end of forec - Business-newsupdate.com - February 17th, 2021
- Human Embryonic Stem Cells Market Analysis By Growth ... - February 9th, 2021
- Pros and Cons of embryonic stem cells - Pros an Cons - February 9th, 2021
- Worldwide Cell Therapy Industry to 2027 - Profiling Allosource, Medipost and Mesoblast Among Others - PRNewswire - February 9th, 2021
- Reactivation of the pluripotency program precedes formation of the cranial neural crest - Science Magazine - February 4th, 2021
- Should We Double The Age When Science Can Experiment On Babies? - 550 KTSA - February 4th, 2021
- Why Cynata is hopeful its COVID treatment trial will succeed where others have failed - Business News Australia - February 4th, 2021
- Missouri State Representative Indicted Over Alleged Stem Cell Therapy Scam - IFLScience - February 4th, 2021
- Global Human Embryonic Stem Cells Market increasing demand with Industry Professionalist |know the Brand Players forecast 2027 Jumbo News - Jumbo... - February 4th, 2021
- Push on to Allow Expanded Human-Embryo Research - National Review - February 4th, 2021
- Stem Cells Market is Expected to Thrive at Impressive CAGR by 2025 Murphy's Hockey Law - Murphy's Hockey Law - February 4th, 2021
- Stem Cell Therapy Market Size, Top Key Players, Applications, Business Statistics, Trends and Forecast 2021-2027 The Bisouv Network - The Bisouv... - February 4th, 2021
- Stem Cell Therapy Market Size to Reach USD 5,040 Million by 2028 | Rising Public-Private Investments and Developing Regulatory Framework for Stem Cell... - January 30th, 2021
- Stem Cell Therapy Market 2021: Global Key Players, Trends, Share, Industry Size, Segmentation, Forecast To 2027 KSU | The Sentinel Newspaper - KSU |... - January 30th, 2021
- Stem Cell Manufacturing includes Attractiveness and Raw Material Analysis and Competitor Position Grid Analysis to 2027 | Merck KGaA, Thermo Fisher... - January 30th, 2021
- RNA Molecules Are Masters of Their Own Destiny Regulating Their Own Production Through a Feedback Loop - SciTechDaily - January 30th, 2021
- The chromosomal protein SMCHD1 regulates DNA methylation and the 2c-like state of embryonic stem cells by antagonizing TET proteins - Science Advances - January 23rd, 2021
- North America to be the Torchbearer to Stem Cell Characterization And Analysis Tools Market NeighborWebSJ - NeighborWebSJ - January 23rd, 2021
- New Research Grant Seeks to Clarify the Role Genes Play in Modulating Inflammation - NYU Langone Health - January 23rd, 2021
- JARID2 and AEBP2 regulate PRC2 in the presence of H2AK119ub1 and other histone modifications - Science Magazine - January 23rd, 2021
- DiNAQOR Acquires EHT Technologies GmbH to Advance Engineered Heart Tissue R&D Capabilities - PRNewswire - January 19th, 2021
- TBC1D3 promotes neural progenitor proliferation by suppressing the histone methyltransferase G9a - Science Advances - January 19th, 2021
- 'He was very honored in his work' - Mercer Island Reporter - December 28th, 2020
- Israeli biotech firm's ALS treatment shows safety of use in trials - The Jerusalem Post - December 16th, 2020
- Ca Bishops To Work w/ Govt on Vaccination Campaigns - Catholic Herald Online - December 14th, 2020
- Human Embryonic Stem Cells (HESC) Market 2019 | Analyzing The Impact Followed By Restraints, Opportunities And Projected Developments | DataIntelo -... - December 6th, 2020
- Stem Cell Market Technology 2021 and Application, Segmentation by Leading Global Players, Market Status by Share and Size Forecast to 2024 - The... - December 6th, 2020
- Stem Cell Therapy Market Size, Opportunities, Dynamic, Outlook and Forecast To 2027 - Cheshire Media - December 6th, 2020
- Stem Cells Market will grow at CAGR of 8.61% by 2027 Cheshire Media - Cheshire Media - December 6th, 2020
- Stem Cell Medical Research to Expand in California Following Passage of Prop. 14 - Times of San Diego - November 27th, 2020
- Mechanisms of Telomere Protection Are Unique in Stem Cells - Technology Networks - November 27th, 2020
- Stem Cells Market by 2020 Research Report by Manufactures, Types, Applications, Regions and Trends to 2024 | Absolute Reports - The Market Feed - November 25th, 2020
- Autologous Stem Cell Based Therapies Market Share, Growth by Top Company, Region, Application, Driver, Trends & Forecasts by 2026 - PRnews Leader - November 25th, 2020
- Stem Cells Market Research Provides an In-Depth Analysis on the Future Growth Prospects and Industry Trends Adopted by the Competitors | (2020-2027),... - November 25th, 2020
- Stem Cells Market 2020: Rising with Immense Development Trends across the Globe by 2027 - The Market Feed - November 25th, 2020
- Global Regenerative Medicine Market 2020-2025: Opportunities with the Implementation of the 21st Century Cures Act - Yahoo Finance - November 25th, 2020
- Stem Cell Characterization and Analysis Tool Market 2020: Potential growth, attractive valuation make it is a long-term investment | Know the COVID19... - November 25th, 2020
- Autologous Stem Cell Based Therapies Market 2020 Emerging Trend and Advancement - News by aeresearch - November 9th, 2020
- Human Embryonic Stem Cells (HESC) Market 2020 Manufacturer Analysis, Emerging Trends, Top Companies and Forecast to 2027 - TechnoWeekly - November 7th, 2020
- Voters asked to approve $5.5 billion for stem cell research - Lebanon Express - November 7th, 2020
- Transcriptional priming as a conserved mechanism of lineage diversification in the developing mouse and human neocortex - Science Advances - November 7th, 2020
- Cell Therapy Manufacturing Market to be Worth USD 8 billion by 2030, predicts Roots Analysis - PRnews Leader - November 7th, 2020
- U.S. elections bring wins and losses for research community - Science Magazine - November 5th, 2020
- Stem Cell Therapy Market Size, Key Development Trends, and Growth Projection to 2027 - Stock Market Vista - November 5th, 2020
- Global Stem Cells Market 2020 Industry Outlook, Growth, Comprehensive Insights and Forecast 2025 - PRnews Leader - November 5th, 2020
- Panelists debate the implications and ethics of stem cell research - Johns Hopkins News-Letter - October 30th, 2020
- Stem Cell and Regenerative Therapy Market to Remain Balanced During the the COVID-19 Period - re:Jerusalem - October 30th, 2020
- Study Identifies Pitfall for Correcting Mutations in Human Embryos with CRISPR - Columbia University Irving Medical Center - October 30th, 2020
- Yale New Haven Health Docs: Interpreting the Uptick in Covid-19 Cases - Greenwich Free Press - October 30th, 2020
- Is the Pro-Life Movement on a Collision Course with the Coronavirus? - The Dispatch - October 29th, 2020
- Outlook for stem cell therapy - its role in tendon regeneration - different treatments for horse tendon injuries - Trainer Magazine - October 29th, 2020
- Yale Health advises against large Thanksgiving gatherings; eastern Connecticut now considered a 'hot spot' - The Westerly Sun - October 29th, 2020
- Stem Cell Therapy Market to Register Unwavering Growth During 2025 - The Think Curiouser - October 29th, 2020
- Human Embryonic Stem Cells (HESC) Market Share, Analysis and In-depth Research on Market Size, Trends, Emerging Growth Factors and Regional Forecasts... - October 20th, 2020
- COVID-19 Analysis to Understand the Competitive Outlook of Human Embryonic Stem Cells (HESC) Market - The Think Curiouser - October 20th, 2020
- Competitive Landscape of Human Embryonic Stem Cells (HESC) Market 2020 | Global Industry Size, Volume, Trends and Revenue Forecast to 2025 - The Think... - October 20th, 2020
- Stem Cells Market 2020 is predicted to rise with a CAGR of XX% by 2026 | Including Growth Prospect, Market Size & Growth, Key Vendors, Top most... - October 20th, 2020
- Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027) - Stock Market Vista - October 20th, 2020
- Global Stem Cell Manufacturing Market: Industry Analysis and forecast 2019 2027: By Product, Application, End-Users and Region - Stock Market Vista - October 20th, 2020
- The Infodemic: Was Regeneron COVID-19 Treatment Developed Using Stem Cells and Fetal Tissue? - Voice of America - October 15th, 2020
- COVID-19 Impact on Global Human Embryonic Stem Cells Market 2020 Industry Overview, Demand and Insights Analysis Report by 2026 ESI BIO, Thermo... - October 15th, 2020
- Yes on 14 | Mailbox | independentnews.com - Livermore Independent - October 15th, 2020
- I've Spent Decades Studying How People Build Their Families. Here's What I've Learned Matters Most - TIME - October 15th, 2020
- Human Embryonic Stem Cells (HESC) Market Size, Regional Insights and Industry Dynamics By 2027 | By Top Leading Vendors Thermo Fisher, Esi Bio,... - September 30th, 2020
- Global Human Embryonic Stem Cells Market 2020 to Witness Huge Growth by 2026 | Top Key Players; Lonza Group Ltd., Life Technologies Corporation,... - September 30th, 2020
- Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027) - Unica News - September 30th, 2020
- Stem Cell Therapy Market Size, Analytical Overview, Key Players, Growth Factors, Demand, Trends And Forecast to 2027 - The Daily Chronicle - September 23rd, 2020
- Stem Cell Manufacturing Market 2020 Global Industry Analysis, Size, Growth, Trends, Share, COVID-19 Impact Analysis, and Forecast 2027| Merck Group,... - September 23rd, 2020
- The Fascinating Story of Q Stock BioRestorative Therapies Inc (OTCMKTS: BRTXQ) - MicroCap Daily - September 18th, 2020
- Global Stem Cell Therapy Market 2020 Research on Import-Export Details, Business Standards and Forecast to 2025 - Scientect - September 18th, 2020
- Study Focuses On New Discovery In Regenerative Medicine | newkerala.com Health News - New Kerala - September 18th, 2020